How did Co‑Diagnostics' Q2 2025 revenue and earnings compare to analyst expectations and prior quarters?

Fundamentals – Co‑Diagnostics posted $45 million in Q2 2025 revenue, a 30 % increase versus Q1 2025 and a 22 % jump over the same quarter a year ago. The top‑line comfortably beat the Street’s consensus forecast of $38 million (the median estimate from Refinitiv and Bloomberg). On the profit side, the company earned $0.12 EPS for the quarter, versus the $0.09 consensus, delivering a 33 % earnings beat and expanding its margin from 18 % in Q1 to 21 % in Q2. The upside reflects the continued rollout of its patented molecular‑diagnostic platform and the addition of three new commercial contracts in Q2, which together contributed roughly $8 million of incremental sales.

Trading implications – The “beat‑and‑beat” on both revenue and earnings has already nudged CODX up 4 % in pre‑market trading, and the upside potential remains priced in. The stock is still trading below its 52‑week high, with the 200‑day moving average (≈$12.30) acting as a near‑term support level. A breakout above the $13.00 resistance—the recent swing‑high—could trigger a short‑term rally toward the $14.50–$15.00 range, where the next resistance and a prior consolidation zone sit. Conversely, a pull‑back below the 200‑day line would likely invite a profit‑taking bounce and re‑test the $11.50–$12.00 support band. Given the strong top‑line beat, expanding margins and the platform’s pipeline visibility, a buy‑on‑dip near $12.00–$12.30 with a stop just below $11.50 is a reasonable way to capture upside while limiting downside.